Isaly steps down from OrbiMed and Worldwide Healthcare Trust Veteran US biotech analyst and OrbiMed Capital founder Samuel Isaly has stepped down from his role as Managing Partner and separately as a director of UK-listed Worldwide Healthcare Trust WWH, which is managed by OrbiMed alongside Biotech Growth Trust BIOG. Isaly will be replaced at the New […]
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
Biotech Growth manager denies allegations – The board of The Biotech Growth Trust says that it notes that the General Partners of OrbiMed Capital LLC, which acts as portfolio manager to the company, released a statement late on 5 December concerning founding partner Samuel Isaly, who is the subject of a press article containing allegations of […]
BioPharma secures second deal for up to $200m – BioPharma Credit PLC has announced that it and BioPharma Credit Investments IV, S.àr.L., entered into a definitive term loan agreement for up to US$200 million with Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), a fully integrated biopharmaceutical company with a current market capitalisation of approximately US$1.0bn. Lexicon markets XERMELO® (teloristat […]
BioPharma Credit makes first major investment since IPO – BioPharma Credit PLC says that, on 21 November 2017, it and BioPharma Credit Investments IV, S.àr.L.entered into a definitive loan agreement for up to US$500 million with TESARO, Inc. (NASDAQ: TSRO), a oncology focused biopharmaceutical company with a market capitalisation of US$4.5 billion. TESARO has commercial […]
International Biotechnology beats benchmark on strong listed portfolio performance – In the year ended 31 August 2017, International Biotechnology Trust’s NAV rose from 575.1p to 672.9p, including a significant currency gain, equivalent to 14.4 pence per share. The NAV returned 20.9% in. Over the same period, the Shareholders total return was 30.5%. This compares to a rise […]
Biotech Growth lags benchmark but shareholders still make 28%. Biotech Growth says that it produced a good return in absolute terms for the year ended 31 March 2017. The net asset value per share rose by 27.5% during the year, which compares with the benchmark, the NASDAQ Biotechnology Index (sterling adjusted), which rose by 29.2%. As […]
